AETOSWire - AETOSWire

AETOSWire distributes your news swiftly across your target audiences to every corner of the world with the latest state-of-the-art technology and innovative solutions that give you the competitive edge you need to get ahead of the competition.

Address

Dubai Media City, Building 1, 3rd Floor, Office 312 P.O. Box 502342 Dubai, United Arab Emirates

+971 4 55 77 007

+971 4 55 77 008

info@aetoswire.com

Quick Links

About us

Services

Newsroom

My Account

Privacy
Terms Of Use
Sitemap

Your experience on this site will be improved by allowing cookies. Cookie Policy

NewsRoom

Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms...

Merck to Present Latest Research From Oncology Portfolio at ASCO...

Merck Shares Advances in MS Portfolio with Key Efficacy and...

Glucophage® Is the First Oral Diabetes Treatment Approved in Europe for...

New MAVENCLAD® Data at ACTRIMS Forum 2022 Show Favourable Efficacy Outcomes...

European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14...

Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab)...

Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

TEPMETKO® (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC...

Merck Highlights Novel Mechanisms with the Potential to Transform Standards...

New Data Presented at ECTRIMS Show Evobrutinib is First BTK...

New Real-World MAVENCLAD® Data Show Sustained Effectiveness and Benefit on Quality-of-Life...

Search...

Search...